Heron Therapeutics, Inc.
HRTXDrugs in Pipeline
17
Phase 3 Programs
6
Upcoming Catalysts
1
Next Catalyst
Aug 14, 2026
16dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How HRTX's past catalysts played out
Bupivacaine HCl
Postoperative Pain
HTX-011
Postoperative Pain
Ondansetron
Chemotherapy-induced Nausea and Vomiting
APF530
Nausea and Vomiting
Ibuprofen
Analgesia
Celecoxib
Analgesia
aprepitant
Postoperative Pain
Bupivacaine HCI without epinephrine
Post-Operative Pain
Ketorolac
Postoperative Pain
HTX-011B
Postoperative Pain
Acetaminophen
Analgesia
B10 L-BPA Injection
Meningioma
HTX-011A
Postoperative Pain
Bupivacaine HCl without epinephrine
Postoperative Pain
Bupivicaine HCl
Postoperative Pain
HTX-034
Bunions
Bupivacaine HCI (Marcaine)
Postoperative Pain
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Bupivacaine HCl | Phase 3 | Postoperative Pain | - | - |
HTX-011 | Phase 3 | Postoperative Pain | - | - |
Ondansetron | Phase 3 | Chemotherapy-induced Nausea and Vomiting | - | - |
APF530 | Phase 3 | Nausea and Vomiting | - | - |
Ibuprofen | Phase 3 | Analgesia | - | - |
Celecoxib | Phase 3 | Analgesia | - | - |
aprepitant | Phase 2 | Postoperative Pain | - | - |
Bupivacaine HCI without epinephrine | Phase 2 | Post-Operative Pain | - | - |
Ketorolac | Phase 2 | Postoperative Pain | - | - |
HTX-011B | Phase 2 | Postoperative Pain | - | - |
Acetaminophen | Phase 2 | Analgesia | - | - |
B10 L-BPA Injection | Phase 2 | Meningioma | - | - |
HTX-011A | Phase 2 | Postoperative Pain | - | - |
Bupivacaine HCl without epinephrine | Phase 2 | Postoperative Pain | - | - |
Bupivicaine HCl | Phase 2 | Postoperative Pain | - | - |
HTX-034 | Phase 2 | Bunions | - | - |
Bupivacaine HCI (Marcaine) | Phase 2 | Postoperative Pain | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Heron Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 17 drug candidates in Heron Therapeutics, Inc.'s (HRTX) pipeline across Phase 3, Phase 2. Its lead program is Bupivacaine HCl (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Heron Therapeutics, Inc.'s next FDA catalyst?→
Heron Therapeutics, Inc.'s (HRTX) next tracked catalyst is a Earnings expected August 14, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track HRTX biotech catalysts?→
Add HRTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Heron Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.